The hidden burden of adult allergic rhinitis

UK healthcare resource utilisation survey

David Price, Glenis Scadding, Dermot Ryan, Claus Bachert, G Walter Canonica, Joaquim Mullol, Ludger Klimek, Richard Pitman, Sarah Acaster, Ruth Murray, Jean Bousquet

Research output: Contribution to journalArticle

34 Citations (Scopus)
3 Downloads (Pure)

Abstract

BACKGROUND: The affliction of allergic rhinitis (AR) has been trivialised in the past. Recent initiatives by the European Academy of Allergy & Clinical Immunology and by the EU parliament seek to rectify that situation. The aim of this study was to provide a comprehensive picture of the burden and unmet need of AR patients.

METHODS: This was a cross-sectional, online, questionnaire-based study (June-July 2011) including symptomatic seasonal AR (SAR) patients (≥18 years) from a panel. SAR episode pattern, severity, medication/co-medication usage, residual symptoms on treatment, number of healthcare visits, absenteeism and presenteeism were collected.

RESULTS: One thousand patients were recruited (mild: n = 254; moderate/severe: n = 746). Patients with moderate/severe disease had significantly more symptomatic episodes/year (8.0 vs 6.0/year; p = 0.025) with longer episode-duration (12.5 vs 9.8 days; p = 0.0041) and more commonly used ≥2 AR therapies (70.5 vs 56.1 %; OR 1.87; p = 0.0001), looking for better and faster nasal and ocular symptom relief. The reported symptom burden was high irrespective of treatment, and significantly (p < 0.0001) higher in the moderate/severe group. Patients with moderate/severe AR were more likely to visit their GP (1.61 vs 1.19 times/year; OR: 1.49; p = 0.0061); due to dissatisfaction with therapy in 35.4 % of cases. Patients reported SAR-related absenteeism from work on 4.1 days/year (total cost to UK: £1.25 billion/year) and noted presenteeism for a mean of 37.7 days/year (vs 21.0 days/year; OR 1.71; p = 0.0048). Asthma co-morbid patients reported the need to increase their reliever- (1 in 2 patients) and controller-medication (1 in 5 patients) if they did not take their rhinitis medication.

CONCLUSIONS: This study differentiated between patients with mild and moderate/severe AR, demonstrating a burden of poorly controlled symptoms and high co-medication use. The deficiency in obtaining symptom control with what are currently considered firstline treatments suggests the need for a novel therapeutic approach.

Original languageEnglish
Article number39
JournalClinical and Translational Allergy
Volume5
Early online date18 Nov 2015
DOIs
Publication statusPublished - 20 Nov 2015

Fingerprint

Delivery of Health Care
Absenteeism
Therapeutics
Allergic Rhinitis
Surveys and Questionnaires
Seasonal Allergic Rhinitis
Rhinitis
Allergy and Immunology
Nose
Hypersensitivity
Asthma
Costs and Cost Analysis

Keywords

  • allergic rhinitis
  • symptom episode
  • UK
  • co-medication
  • absenteeism
  • presenteeism

Cite this

The hidden burden of adult allergic rhinitis : UK healthcare resource utilisation survey. / Price, David; Scadding, Glenis; Ryan, Dermot; Bachert, Claus; Canonica, G Walter; Mullol, Joaquim; Klimek, Ludger; Pitman, Richard; Acaster, Sarah; Murray, Ruth; Bousquet, Jean.

In: Clinical and Translational Allergy, Vol. 5, 39, 20.11.2015.

Research output: Contribution to journalArticle

Price, D, Scadding, G, Ryan, D, Bachert, C, Canonica, GW, Mullol, J, Klimek, L, Pitman, R, Acaster, S, Murray, R & Bousquet, J 2015, 'The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey', Clinical and Translational Allergy, vol. 5, 39. https://doi.org/10.1186/s13601-015-0083-6
Price, David ; Scadding, Glenis ; Ryan, Dermot ; Bachert, Claus ; Canonica, G Walter ; Mullol, Joaquim ; Klimek, Ludger ; Pitman, Richard ; Acaster, Sarah ; Murray, Ruth ; Bousquet, Jean. / The hidden burden of adult allergic rhinitis : UK healthcare resource utilisation survey. In: Clinical and Translational Allergy. 2015 ; Vol. 5.
@article{80283976feca4adfac30f31f2a473ac8,
title = "The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey",
abstract = "BACKGROUND: The affliction of allergic rhinitis (AR) has been trivialised in the past. Recent initiatives by the European Academy of Allergy & Clinical Immunology and by the EU parliament seek to rectify that situation. The aim of this study was to provide a comprehensive picture of the burden and unmet need of AR patients.METHODS: This was a cross-sectional, online, questionnaire-based study (June-July 2011) including symptomatic seasonal AR (SAR) patients (≥18 years) from a panel. SAR episode pattern, severity, medication/co-medication usage, residual symptoms on treatment, number of healthcare visits, absenteeism and presenteeism were collected.RESULTS: One thousand patients were recruited (mild: n = 254; moderate/severe: n = 746). Patients with moderate/severe disease had significantly more symptomatic episodes/year (8.0 vs 6.0/year; p = 0.025) with longer episode-duration (12.5 vs 9.8 days; p = 0.0041) and more commonly used ≥2 AR therapies (70.5 vs 56.1 {\%}; OR 1.87; p = 0.0001), looking for better and faster nasal and ocular symptom relief. The reported symptom burden was high irrespective of treatment, and significantly (p < 0.0001) higher in the moderate/severe group. Patients with moderate/severe AR were more likely to visit their GP (1.61 vs 1.19 times/year; OR: 1.49; p = 0.0061); due to dissatisfaction with therapy in 35.4 {\%} of cases. Patients reported SAR-related absenteeism from work on 4.1 days/year (total cost to UK: £1.25 billion/year) and noted presenteeism for a mean of 37.7 days/year (vs 21.0 days/year; OR 1.71; p = 0.0048). Asthma co-morbid patients reported the need to increase their reliever- (1 in 2 patients) and controller-medication (1 in 5 patients) if they did not take their rhinitis medication.CONCLUSIONS: This study differentiated between patients with mild and moderate/severe AR, demonstrating a burden of poorly controlled symptoms and high co-medication use. The deficiency in obtaining symptom control with what are currently considered firstline treatments suggests the need for a novel therapeutic approach.",
keywords = "allergic rhinitis, symptom episode, UK, co-medication, absenteeism, presenteeism",
author = "David Price and Glenis Scadding and Dermot Ryan and Claus Bachert and Canonica, {G Walter} and Joaquim Mullol and Ludger Klimek and Richard Pitman and Sarah Acaster and Ruth Murray and Jean Bousquet",
note = "Funding Funding for this survey was provided by Meda Pharma.",
year = "2015",
month = "11",
day = "20",
doi = "10.1186/s13601-015-0083-6",
language = "English",
volume = "5",
journal = "Clinical and Translational Allergy",
issn = "2045-7022",
publisher = "BioMed Central",

}

TY - JOUR

T1 - The hidden burden of adult allergic rhinitis

T2 - UK healthcare resource utilisation survey

AU - Price, David

AU - Scadding, Glenis

AU - Ryan, Dermot

AU - Bachert, Claus

AU - Canonica, G Walter

AU - Mullol, Joaquim

AU - Klimek, Ludger

AU - Pitman, Richard

AU - Acaster, Sarah

AU - Murray, Ruth

AU - Bousquet, Jean

N1 - Funding Funding for this survey was provided by Meda Pharma.

PY - 2015/11/20

Y1 - 2015/11/20

N2 - BACKGROUND: The affliction of allergic rhinitis (AR) has been trivialised in the past. Recent initiatives by the European Academy of Allergy & Clinical Immunology and by the EU parliament seek to rectify that situation. The aim of this study was to provide a comprehensive picture of the burden and unmet need of AR patients.METHODS: This was a cross-sectional, online, questionnaire-based study (June-July 2011) including symptomatic seasonal AR (SAR) patients (≥18 years) from a panel. SAR episode pattern, severity, medication/co-medication usage, residual symptoms on treatment, number of healthcare visits, absenteeism and presenteeism were collected.RESULTS: One thousand patients were recruited (mild: n = 254; moderate/severe: n = 746). Patients with moderate/severe disease had significantly more symptomatic episodes/year (8.0 vs 6.0/year; p = 0.025) with longer episode-duration (12.5 vs 9.8 days; p = 0.0041) and more commonly used ≥2 AR therapies (70.5 vs 56.1 %; OR 1.87; p = 0.0001), looking for better and faster nasal and ocular symptom relief. The reported symptom burden was high irrespective of treatment, and significantly (p < 0.0001) higher in the moderate/severe group. Patients with moderate/severe AR were more likely to visit their GP (1.61 vs 1.19 times/year; OR: 1.49; p = 0.0061); due to dissatisfaction with therapy in 35.4 % of cases. Patients reported SAR-related absenteeism from work on 4.1 days/year (total cost to UK: £1.25 billion/year) and noted presenteeism for a mean of 37.7 days/year (vs 21.0 days/year; OR 1.71; p = 0.0048). Asthma co-morbid patients reported the need to increase their reliever- (1 in 2 patients) and controller-medication (1 in 5 patients) if they did not take their rhinitis medication.CONCLUSIONS: This study differentiated between patients with mild and moderate/severe AR, demonstrating a burden of poorly controlled symptoms and high co-medication use. The deficiency in obtaining symptom control with what are currently considered firstline treatments suggests the need for a novel therapeutic approach.

AB - BACKGROUND: The affliction of allergic rhinitis (AR) has been trivialised in the past. Recent initiatives by the European Academy of Allergy & Clinical Immunology and by the EU parliament seek to rectify that situation. The aim of this study was to provide a comprehensive picture of the burden and unmet need of AR patients.METHODS: This was a cross-sectional, online, questionnaire-based study (June-July 2011) including symptomatic seasonal AR (SAR) patients (≥18 years) from a panel. SAR episode pattern, severity, medication/co-medication usage, residual symptoms on treatment, number of healthcare visits, absenteeism and presenteeism were collected.RESULTS: One thousand patients were recruited (mild: n = 254; moderate/severe: n = 746). Patients with moderate/severe disease had significantly more symptomatic episodes/year (8.0 vs 6.0/year; p = 0.025) with longer episode-duration (12.5 vs 9.8 days; p = 0.0041) and more commonly used ≥2 AR therapies (70.5 vs 56.1 %; OR 1.87; p = 0.0001), looking for better and faster nasal and ocular symptom relief. The reported symptom burden was high irrespective of treatment, and significantly (p < 0.0001) higher in the moderate/severe group. Patients with moderate/severe AR were more likely to visit their GP (1.61 vs 1.19 times/year; OR: 1.49; p = 0.0061); due to dissatisfaction with therapy in 35.4 % of cases. Patients reported SAR-related absenteeism from work on 4.1 days/year (total cost to UK: £1.25 billion/year) and noted presenteeism for a mean of 37.7 days/year (vs 21.0 days/year; OR 1.71; p = 0.0048). Asthma co-morbid patients reported the need to increase their reliever- (1 in 2 patients) and controller-medication (1 in 5 patients) if they did not take their rhinitis medication.CONCLUSIONS: This study differentiated between patients with mild and moderate/severe AR, demonstrating a burden of poorly controlled symptoms and high co-medication use. The deficiency in obtaining symptom control with what are currently considered firstline treatments suggests the need for a novel therapeutic approach.

KW - allergic rhinitis

KW - symptom episode

KW - UK

KW - co-medication

KW - absenteeism

KW - presenteeism

U2 - 10.1186/s13601-015-0083-6

DO - 10.1186/s13601-015-0083-6

M3 - Article

VL - 5

JO - Clinical and Translational Allergy

JF - Clinical and Translational Allergy

SN - 2045-7022

M1 - 39

ER -